Jeffrey Epstein's Foray into Regenerative Medicine
Newly released U.S. Department of Justice archives reveal the extent of Jeffrey Epstein's ambitions in genetic research and regenerative medicine. The convicted sex offender intended to fund projects involving gene editing to slow human aging. He collaborated with Dr. Joseph Thakuria, a senior physician at Massachusetts General Hospital and a Harvard Medical School researcher, who presented him with a private genome sequencing project. This proposal involved using CRISPR technology to introduce mutations with the theoretical goal of extending lifespan.
The disclosed documents include an invoice for over $193,000, which Epstein paid for initial studies on his fibroblasts and partial DNA sequencing. Harvard Medical School has publicly distanced itself from the private arrangements Epstein made with Thakuria. Furthermore, a proposed $160,000 project named 'Venus,' which aimed to study the genetics of facial features with about 200 participants, was never realized.
The Political Fallout of the Epstein Case
Epstein was also a donor to Humanity+, an organization that promotes transhumanism. The ongoing revelations from his case continue to create political ripples. For instance, UK Prime Minister Keir Starmer's appointment of Peter Mandelson as ambassador to Washington has drawn scrutiny, given Mandelson's maintained relationship with Epstein after his 2008 conviction.
Donald Trump: 'I have nothing to do with it. I have nothing to do with Jeffrey Epstein.'
The release of these archives underscores the complex intersection of Epstein's scientific ventures and their potential impact on modern politics and society. These details raise profound ethical questions for the scientific community about engaging with funders of compromised character. The situation highlights the critical need for rigorous vetting of funding sources to protect the integrity and public trust in scientific research, a principle that extends far beyond this single case.